Skip to main content

Valneva SE

corporate_fare Company Profile

Valneva SE

VALN·NASDAQ·Life Sciences·CIK 0001836564

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases. The company focuses on providing first-, best-, or only-in-class vaccine solutions. Valneva currently markets three proprietary travel vaccines. Its clinical portfolio includes vaccine candidates designed to provide preventative solutions for diseases with high unmet need. The company's pipeline includes VLA15, a Lyme disease vaccine candidate in advanced clinical development, which is being developed in partnership with Pfizer. VLA15 is a Phase 3 vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease, and is the only vaccine candidate against Lyme disease currently undergoing late-stage clinical trials. Pfizer and Valneva are executing the Phase 3 field efficacy trial for VLA15, called VALOR (Vaccine Against Lyme for Outdoor Recreationists). Vaccinations were completed in July 2025, and participants were monitored for Lyme disease cases until the end of 2025. VLA15 targets the six most prevalent serotypes of Borrelia in the Northern Hemisphere. Approximately 476,000 people are diagnosed with Lyme disease each year in the United States, and at least 132,000 cases occur annually in Europe. Valneva's pipeline also includes the world's most clinically advanced tetravalent Shigella vaccine candidate, under development in collaboration with LimmaTech Biologics AG. Additionally, VLA1553 is a single-dose, live-attenuated vaccine against chikungunya, currently marketed outside the United States under the brand name IXCHIQ. This product continues to be evaluated in ongoing Phase 3/4 clinical trials, including post-marketing studies.

Valneva SE (NASDAQ:VALN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for VALN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Valneva Withdraws Chikungunya Vaccine BLA/IND in U.S. Following FDA Suspension and Clinical Hold

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
€174.66M EUR
Net Income
-€115.19M EUR
Diluted EPS
-€0.68 EUR
Op. Cash Flow
-€52.89M EUR
Free Cash Flow
-€57.31M EUR
Gross Profit
€67.52M EUR
Operating Income
-€82.06M EUR
Cash & Equivalents
€109.65M EUR
Total Debt
€161.26M EUR
Debt / Equity
1.52×
Net Margin
-66.0%
Shares Outstanding
173.54M sh
Source: 20-F · filed 2026-03-17 · accession 0001628280-26-018808

Insider Transactions

VALN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$5.16 -3.82% today
52-week range · as of 2026-11-13 $4.75 – $12.18
Market cap
$492.93M
Volume
17.6K (1.1× avg)
3-mo avg 16.5K
Live data · 2026-11-22 12:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VALN - Filings & News (Page 2)

VALN
Jan 20, 2026, 9:50 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $9.63
Real-time Price: $5.16 info
Change: -$4.47 (-46%) info
Market Cap: $492.925M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets